Recombinant Mouse G-CSF Protein (C-6His)

Name: Recombinant Mouse G-CSF Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0722NP
Price: 368.0 USD
Availability: InStock

BL-0722NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Colony-stimulating factors and receptors (csfs), Cytokines, Cytokines and growth factors, Growth factors and receptors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Mouse Granulocyte Colony-Stimulating Factor is produced by our Mammalian expression system and the target gene encoding Val31-Ala208 is expressed with a 6His tag at the C-terminus.
Accession	P09920
Synonym	Granulocyte colony-stimulating factor; Csf3; G-CSF
Gene Background	Granulocyte colony-stimulating factor (G-CSF) is a growth factor and an essential cytokine which belongs to the IL-6 superfamily. Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. G-CSF binding to its receptor G-CSF-R which belongs to the cytokine receptor type I family depends on the interaction of alpha-helical motifs of the former and two fibronectin type III as well as an immunoglobulin-like domain of the latter. G-CSF is a cytokine that have been demonstrated to improve cardiac function and perfusion in myocardial infarction. And it was initially evaluated as a stem cell mobilizer and erythropoietin as a cytoprotective agent.
Molecular Mass	19.8 KDa
Apmol Mass	25 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 10mM Sodium Citrate, 0.1% Tween 20, pH 3.5.
Endotoxin	Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes.
Subcellular Location	Secreted.
Protein Families	IL-6 superfamily
Database References	KEGG: mmu:12985 STRING: 10090.ENSMUSP00000037762 UniGene: Mm.1238

Gene Functions References

We confirmed that acute lung injury was associated with high serum G-CSF levels, and elevated neutrophil elastase activity in the lungs and serum of mice with adenine-induced acute kidney injury (AKI). G-CSF could be a target for new anti-lung injury strategy in patients with AKI. PMID: 30056257
The opposing roles of G-CSF and IFNgamma in regulation of innate inflammatory responses in a murine viral encephalitis model reveal G-CSF as a potential therapeutic target. PMID: 29352287
central regulator of the transition to postinflammatory chronic visceral pain PMID: 28973941
We propose that in aggressive pancreatic ductal adenocarcinoma , elevated G-CSF contributes to tumor progression through promoting increases in infiltration of neutrophil-like cells with high immunosuppressive activity. Such a mechanism provides an avenue for a neoadjuvant therapeutic approach for this devastating disease PMID: 28775207
these data provide strong evidence for a role for G-CSF in the development of ACI after burn injury through suppression of EPO signaling in bone marrow erythroid cells. PMID: 28867537
physiologically produced G-CSF not only acts as a neutrophil mobilizer at the relatively late stage of acute inflammation, but also prevents exaggerated neutrophil mobilization. PMID: 27551153
data demonstrate that G-CSF is a pivotal driver of the disease progression in the K/BxN serum-transfer arthritis (STA) model and possibly acts in part by regulating neutrophil numbers in the circulation PMID: 26848119
SB203580 increases G-CSF expression in macrophages by increasing the stability of G-CSF mRNA via its 3'UTR, and the effect was not due to its inhibition of p38 MAPK activity. PMID: 26772539
Results suggested that G-CSF plays an important role in preventing colitis, likely through populating immune regulatory macrophages in the intestine. PMID: 26687628
findings provide convincing evidence that monophosphoryl lipid A-induced G-CSF facilitates early expansion, mobilization, and recruitment of neutrophils to the site of infection after burn injury PMID: 26538529
Overexpression of VEGF may compensate for the G-CSF deficit through preservation of cellular components, including blood vessels, in the postinfarction heart. PMID: 25976246
rapidly induces autophagy after spinal cord injury to inhibit neuronal apoptosis PMID: 26524416
G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy. PMID: 25865621
constitutive activation of the NF-kappaB pathway in CAIX-depleted cells restored G-CSF secretion PMID: 25623234
Exposure of Sca-1(+) cells to G-CSF in the culture medium for 72 h induced time-dependent but self-limiting cell cycle acceleration with a restricted effect on the CSC proliferation. PMID: 25160782
these results suggest that the G-CSF pathway regulates the production of autoantibodies in murine models of lupus. PMID: 23566364
G-CSF acts in a cell intrinsic manner to expand multipotent progenitors to increase production of tumor-derived Ly6G+ neutrophils. PMID: 25624500
Endothelial cell(EC)-intrinsic MYD88 signaling and subsequent G-CSF production by ECs is required for myeloid progenitor lineage skewing toward granulocyte-macrophage progenitors, increased colony-forming unit granulocyte activity. PMID: 24990886
Adventitial CXCL1/granulocyte-colony stimulating factor expression in response to aortic dissection triggers local neutrophil recruitment and activation. This leads to adventitial inflammation via IL-6 and results in aortic expansion and rupture. PMID: 25563839
Cultured mouse enteric nervous system -neurospheres show increased expansion with increased G-CSF concentrations, in contrast to central nervous system - derived spheres. PMID: 24253464
G-CSF STAT3 axis constitutes a key protective mechanism induced by injury to reduce the risk for posttraumatic infection. PMID: 24470495
After deletion of Pten in mice lacking G-CSF, the splenomegaly, myeloproliferative disease, and splenic hematopoietic stem cell accumulation are rescued. PMID: 24127490
Our results suggest 5-AED survival enhancement is G-CSF-dependent, and that it stimulates innate immune cell function and reduces radiation-induced DNA damage via induction of genes that modulate cell cycle progression and apoptosis. PMID: 22843381
activation of the RAS/MEK/ERK pathway regulates G-CSF expression through the Ets transcription factor PMID: 23530240
G-CSF protein is necessary and sufficient to restore monocyte chemoattractant protein (MCP)-1 deficiency in neutrophil-mediated host immunity following Klebsiella pneumoniae lung infection. PMID: 23129755
Ang2 deficiency results in enhanced recruitment of myeloid cells depending on G-CSF, and that the enhancement results in more aggressive tumor growth and neo-angiogenesis during liver colonization. PMID: 22699974
Il-1rn knockout mice exhibit delayed resolution in acute lung inflammation after exposure to lipopolysaccharide, a process that appears to be mediated via the granulocyte colony-stimulating factor/IL-17A axis. PMID: 22592923
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. PMID: 22528488
BMMCs and G-CSF co-administration exhibits synergistic beneficial effect over time. PMID: 21699735
granulocyte and macrophage populations of murine bone marrow cells are regulated by G-CSF and CD137 protein PMID: 21179444
TLR2 signaling in G-CSF mobilized PBSCs correlates with their ability to rapidly differentiate into myeloid cells, resulting in improved engraftment PMID: 21239180
G-CSF is crucial for skeletal myocyte development and regeneration PMID: 21422169
G-CSF and IL-6 provide signals that determine the angiogenic potential of BM resident monocytes. PMID: 20354107
G-CSF stimulates the expression of the MIP-2 receptor via STAT3-dependent transcriptional activation of Il8rb PMID: 20185584
G-CSF exerts potent anti-apoptotic activities towards motoneurons in vivo and suggests that the protection offered by G-CSF in ALS mouse models is due to its direct neuroprotective activity PMID: 20178614
Overexpression of STAT3beta did not alter the kinetics of G-CSF-mediated neutrophilic differentiation or p27 induction in 32D/G-CSF-R WT cells. PMID: 11920194
Increased production of G-CSF in mice mounting the acute phase response is a key physiological component of host defense. PMID: 12097396
Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation using G-CSF-deficient mice PMID: 12130495
G-CSF induces neutrophil mobilization indirectly through the generation of trans-acting signals PMID: 12387736
G-CSF mediates granulopoiesis and, as a corollary, participates in neutrophilia in LFA-1 deficient mice. PMID: 12734371
regulation of G-CSF levels may provide a mechanism for directing primitive hematopoietic progenitors into the common myeloid lineage in response to environmental stresses PMID: 12893769
G-CSF treatment leads to Lyn-mediated tyrosine phosphorylation of Gab2, which may serve as an important intermediate of enhanced Akt activity and myeloid differentiation, not growth/survival response. PMID: 14656892
G-CSF signaling in neutrophils is negatively regulated by SOCS3 PMID: 14699146
observations show that lipocalin 24p3 is not involved in the granulocyte-colony stimulating factor withdrawal-induced apoptosis PMID: 14703690
critical role for G-CSF in driving joint inflammation and as a potential therapeutic target in inflammatory joint diseases, such as rheumatoid arthritis. PMID: 15272075
G-CSF induces stabilization of Fli-1 protein in myeloid cells PMID: 15557108
G-CSF treatment significantly improved survival and liver histology in chemically injured mice, predominantly by promoting endogenous repair mechanisms; immunohistochemistry showed a higher percentage of bone marrow-origin hepatocytes PMID: 15661404
Febrile-range hyperthermia-induced expression of G-CSF drives the sustained peripheral neutrophilia that occurs during sustained (36 h) hyperthermia in a conscious temperature-clamped mouse model. PMID: 15829718
G-CSF modulates angiogenesis by increasing myelomonocytic cells (VEGFR1+ neutrophils) and their release of VEGF PMID: 16223785
monocytes mobilized into the blood by G-CSF or AMD3100 stimulate angiogenesis at sites of ischemia through a paracrine mechanism PMID: 16735597

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.